earnings
confidence high
sentiment positive
materiality 0.78
Halozyme Q2 revenue $326M (+41% YoY); raises FY25 guidance, files patent suit vs Merck
HALOZYME THERAPEUTICS, INC.
2025-Q2 EPS
reported $2.26
vs consensus $1.29
▲ beat
(+75.0%)
- Q2 total revenue $325.7M (+41% YoY); royalty revenue $205.6M (+65% YoY).
- GAAP diluted EPS $1.33 (+85% YoY); Non-GAAP diluted EPS $1.54 (+69% YoY).
- Raises 2025 total revenue guidance to $1.275-1.355B (26-33% YoY) and Non-GAAP EPS to $6.00-6.40.
- Completed $303M share repurchases in Q2; initiated third $250M tranche under $750M program.
- Filed patent infringement lawsuit against Merck alleging unauthorized use of MDASE technology for SC Keytruda.